[Cross and non-cross resistant anticancer agents to multidrug-resistant cultured cells from hematologic malignancies].
We report here that typical and atypical multidrug resistant (MDR) cells can be identified by monoclonal antibodies, MRK16 and MRK20, respectively. Typical MDR cells were cross-resistant to vinca alkaloids, anthracyclines, mitoxantrone (MXT), etoposide (VP-16) and actinomycin-D (ACT-D), and reactive to MRK16. Atypical MDR cells were cross-resistant to anthracyclines, MXT, VP-16, and bleomycin but sensitive to vinca alkaloids and ACT-D. They were reactive to MRK20, but not to MRK16. Among anthracyclines, aclacinomycin A was not cross-resistant to either typical or atypical MDR cells. Methotrexate was not cross-resistant to doxorubicin, vincristine, Ara-C and cisplatin. Cisplatin was not cross resistant to 5-FU, either. Identification of cross and non-cross resistant anticancer agents may be useful to plan a cure-oriented combination chemotherapy for hematologic malignancies.
Shimoyama
M
M
Hematology-Oncology and Clinical Cancer Chemotherapy Division, National Cancer Center Hospital.
Ishida
Y
Y
Ohtsu
T
T
Shimada
Y
Y
Tobinai
K
K
Minato
K
K
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002460:Cell Line; D004351:Drug Resistance; D006801:Humans; D066298:In Vitro Techniques; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents